In the PARADIGM-HF [Prospective Comparison of Angiotensin Receptor/Neprilysin Inhibitor (ARNI) Sacubitril/Valsartan (SV) with Angiotensin-converting Enzyme Inhibitor (ACEi) to Determine Impact on Global Mortality and Morbidity in Heart Failure (HF) trial], SV (LCZ696) significantly reduced cardiovascular (CV) mortality and HF hospitalization, compared to enalapril in patients with HF with reduced ejection fraction (HFrEF)1. This evidence concerns the gene MME and hydrops fetalis.